



Use of in vitro 3D tissue models in genotoxicity testing: strategic fit, validation 
status and way forward. Report of the working group from the 7th International 
workshop on genotoxicity testing (IWGT) 
Stefan Pfuhler1*, Jan van Benthem2, Rodger Curren3, Shareen Doak4, Maria Dusinska5, Makoto 
Hayashi6, Robert H. Heflich7, Darren Kidd8, David Kirkland9, Yang Luan10, Gladys Ouedraogo11, 
Kerstin Reisinger12, Toshio Sofuni13, Frédérique van Acker14, Ying Yang15, Raffaella Corvi16 
 
1 Procter and Gamble, Mason Business Centre, Mason, OH, USA 
2 National Institute for Public Health and the Environment, Centre for Health Protection, Bilthoven, The 
Netherlands 
3 Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA 
4 Swansea University Medical School, Singleton Park, Swansea, SA2 8PP, Wales, UK 
5 Health Effects Laboratory, MILK, NILU-Norwegian Institute for Air Research, Kjeller, Norway 
6 makoto international consulting, Ebina, Japan 
7 U.S. Food and Drug Administration/National Center for Toxicological Research, Jefferson, AR USA 
8 Covance Laboratories Ltd, Otley Road, Harrogate, HG3 1PY, UK  
9 Kirkland Consulting, PO Box 79, Tadcaster LS24 0AS, UK  
10 School of Public Health, Hongqiao International Institute of Medicine, Shanghai Jiao Tong University School of 
Medicine, Shanghai 200025, P. R. China. 
11 L’Oréal R&I, Aulnay-sous-bois, France 
12 Henkel AG & Co KGaA, Duesseldorf, Germany 
13 Formerly National Institute of Health Sciences, Tokyo, Japan 
14 Triskelion B.V., Zeist, The Netherlands 
15 Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, P. R. China. 







Use of three-dimensional (3D) tissue equivalents in toxicology has been increasing over the last decade 
as novel preclinical test systems and as alternatives to animal testing. In the area of genetic toxicology, 
progress has been made with establishing robust protocols for skin, airway (lung) and liver tissue 
equivalents. In light of these advancements, a “Use of 3D Tissues in Genotoxicity Testing” working group 
(WG) met at the 7th IWGT meeting in Tokyo, November 2017 to discuss progress with these models and 
how they may fit into a genotoxicity testing strategy. The workshop demonstrated that skin models have 
reached an advanced state of validation following over 10 years of development, while liver and airway 
model-based genotoxicity assays show promise but are at an early stage of development. Further effort 
in liver and airway model-based assays is needed to address the lack of coverage of the three main 
endpoints of genotoxicity (mutagenicity, clastogenicity and aneugenicity), and information on metabolic 
competence. The IWGT WG believes that the 3D skin comet and micronucleus assays are now 
sufficiently validated to undergo an independent peer review of the validation study, followed by 







Use of three-dimensional (3D) tissue equivalents in toxicology has been increasing over the last decade 
as novel preclinical test systems and as alternatives to animal testing [1-3]. In the area of genetic 
toxicology, progress with establishing robust protocols has been made for skin, airway and liver tissue 
equivalents. In light of these advancements, a “Use of 3D Tissues in Genotoxicity Testing” working group 
(WG) was formed that met at the 7th IWGT meeting in Tokyo, November 2017.  
Previous expert panels discussed the potential use and status of these assays and helped set the stage 
for the 2017 WG meeting. More specifically, at the 2009 IWGT meeting the WG “In vitro genotoxicity 
test approaches with better predictivity” discussed the best developed and most frequently used 
models based on human 3D reconstructed skin (RS). This WG agreed that RS-based genotoxicity models, 
once validated, will be useful to follow up on positive results from standard in vitro assays for dermally 
applied compounds [4]. It became clear, however, that more work was needed to ensure a robust model 
and the testing of more coded chemicals was recommended, as well as further evaluation of the 
metabolic capacity of the RS models. A broader discussion about the use of in vitro tissue equivalents, 
going beyond skin models, was held at the "New Technologies” Workshop in 2012 in Washington, 
hosted by the Health and Environmental Sciences Institute (HESI) Genetic Toxicology Technical 
Committee (GTTC) [5]. The strengths and weaknesses of 3D skin, airway and liver models were discussed 
at the Workshop. The Workshop report acknowledged that the ‘in vivo-like’ behavior of 3D tissue 
constructs was an important advantage of these models and recommended them as superior in this 
regard than the standard 2D static cell culture systems, which they concluded were artificial and far 
removed from the in vivo state. Conversely, it was noted that 3D tissue-based assays are more 
technically difficult to perform, more expensive, and have a lower throughput than assays conducted 
with 2D cell cultures. It was also noted that, at that time, assays with 3D cultured systems were used 
only in a small number of laboratories.  
At the IWGT in Tokyo, a diverse WG, comprised of representatives from regulatory institutions, 
academia and industry from Asia, North America and Europe, was chartered with the task of reviewing 
recent progress with the development, optimization and validation of in vitro tissue models for 
genotoxicity testing. The WG consisted of subject matter experts, some of whom were bringing 
experimental data to the WG to enable efficient and evidence-based discussions towards the specific 
WG goals, which were:  




 Discuss the validation status of these assays and their fit in a genotoxicity testing strategy 
 Develop recommendations for further development of these assays and capture consensus 
statements 
 
2. Experimental data presented/discussed 
a. 3D liver models in genotoxicity testing  
Liver spheroids can be readily constructed from hepatocytes and one such model has been developed 
using HepG2 hepatocellular carcinoma cells, based upon growth in a hanging-drop format [6]. When 
HepG2 cells are cultured in this 3D spheroid format, they exhibit a substantial increase in liver-specific 
functionality, expressing significantly higher CYP1A1/2 activities and production of albumin and urea 
than the same cells grown in 2D monolayer format [6]. A protocol for utilizing 3D HepG2 liver spheroids 
with the cytokinesis blocked micronucleus (CBMN) assay has been established. To evaluate their 
suitability for genotoxicity testing in the CBMN assay, 3D HepG2 spheroids were exposed to the pro-
carcinogens, benzo[a]pyrene (BaP) and 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP). The 
performance of the standard CBMN assay in HepG2 cell monolayers (2D) was then compared to the 3D 
HepG2 spheroid assay [6]. Following exposure to BaP, the first significant increase (p< 0.05) in 
micronucleus (MN) frequency occurred at 3 μM BaP in both 2D monolayers and the 3D HepG2 hanging-
drop spheroids; however, the MN frequency induced by this concentration of BaP in the 3D hanging-
drop spheroids was 2-fold higher than in 2D monolayers. With respect to PhIP, the lowest observable 
effect level occurred at a lower concentration when the 3D liver spheroids were exposed to the 
compound, as compared to the standard 2D test system. The lowest concentration that resulted in a 
significant induction of micronuclei in the 3D hanging-drop spheroids was 5 μM PhIP, while in the 2D 
HepG2 culture system, it was 10 μM PhIP. Furthermore, the level of genotoxicity induced by this lowest 
observable effect level in the 3D spheroids was nearly 2-fold higher than in the standard 2D CBMN 
assay. Thus, both BaP and PhIP exhibited significantly higher MN frequencies at the same concentrations 
in the 3D models than in the standard 2D monolayer cultures of HepG2 cells. Additionally, PhIP was 
positive for genotoxicity at a lower concentration in the 3D model than in the 2D CBMN assay [6]. This 
higher level of chromosomal damage in the 3D CBMN assay with both BaP and PhIP is thought to be due 
to the higher metabolic activity exhibited in the HepG2 cells when cultured in a spheroid format, which 
more efficiently converts these compounds into their genotoxic metabolites. 
 




Human 3D airway models (sometimes referred to as lung models) consist of fully differentiated and 
functional human respiratory epithelium, including cilia, mucus layer, etc., and allow relevant exposure 
to air as they are cultured at an air-liquid interface (ALI). These models are formed from primary cultures 
of human airway epithelial cells (typically from the large airway of donor lungs at autopsy) which are 
allowed to differentiate at the ALI over approximately one month to form a mixture of basal, ciliated, 
goblet and possibly club cells, forming a layer of cells that closely resembles the lining of the human 
airway ([7]). It is anticipated that these models may enable a more realistic (geno)toxicity assessment of 
inhaled compounds; and unlike the RS models, these tissue equivalents remain stable in culture for 
months, opening the possibility of using subchronic treatments similar to those used in vivo. 
A protocol for the comet assay was established using two commercially available human reconstructed 
3D airway models (MucilAir™ produced by Epithelix Sàrl, Switzerland and EpiAirway™ produced by 
MatTek Corporation, US) and one model developed in-house (LUMC, The Netherlands). Background 
levels of DNA damage in both of the commercially available and in the in-house untreated models were 
low, and concentration-related responses were observed following treatment with various well known 
genotoxins, such as methyl methane sulfonate (MMS), 4-nitroquinolone-N-oxide (4-NQO) and 
cyclophosphamide (CP) (Figure 1). Positive responses for DNA damage using the comet assay also have 
been reported recently for 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone (NNK) by the US FDA/NCTR 
using a human ALI airway culture system developed in-house [8]. In addition to the comet assay, a 
protocol for the CBMN assay was applied. After several experiments to establish conditions for 
generating slides of good quality (with respect to cell density, nuclei and cytoplasm), it was concluded 
that the rate of cell division was too low to obtain a sufficient number of binucleated cells, making the 
detection of micronuclei less sensitive (Figure 2). 
The performance of the comet assay in a commercially available human 3D airway model, MucilAir™, 
was compared to the routinely used bronchial epithelial cell line BEAS-2B and the tumor cell line A549, 
which resemble alveolar pneumocyte Type II cells [9]. Upon receipt, the MucilAir models were 
maintained in culture (on 24-well Transwell™ culture supports) at the air-liquid interface using MucilAir 
culture medium. For air–liquid exposures of the A549 and BEAS-2B cells, cells were seeded onto track-
etched polyethylene terephthalate (PET) membrane inserts. After 72 h, the inserts were ‘air-lifted’ (i.e., 
culture medium was removed from the apical side of the inserts) and the cells were cultured for 16–24 h 
before exposure with the apical surface exposed to air, while the basal surface was fed with medium 
through the membrane support. Cerium oxide nanoparticles (CeO2; primary particle size 13.8 nm) were 
applied to the apical surface of the cultures via a dynamic airflow using the Vitrocell® system. The 




leakage (Figure 3A) and IL-8 release (Figure 3B) and expressed relative to the incubator controls (not 
exposed to an air stream). Exposure to air alone did not increase the LDH and IL-8 responses in 
MucilAir™ compared to incubator controls, but in both BEAS-2B and A549 cells, it resulted in significant 
increases [9]. This is most likely due to the protective morphology of the ALI culture, having cilia, mucus 
layer, etc. similar to the lining of the human airway. Aerosolizing CeO2 resulted in agglomeration or 
aggregation of particles. Such agglomerates or aggregates are likely to be the predominant form of 
particle that interact with all types of cells. Only 14% of particles were below 100 nm and the mean 
particle size was 300 nm. The deposited concentrations of CeO2 particles for the A549 and BEAS-2B cells 
were 0.04, 0.16, and 0.71 µg/cm2. MucilAir models received 0.15, 0.67, and 3.0 µg/cm2. Cellular 
responses to exposure via air to different concentrations of CeO2 for 1 hour varied according to cell type 
tested. Exposure of the MucilAir cultures did not result in significant effects in terms of inflammatory or 
cytotoxicity parameters and genotoxicity (comet assay), but it did affect the cell lines. Conversely, 
oxidative stress (increased Heme oxygenase 1 protein expression) was observed in the MucilAir cultures 
but not in the cell lines. This suggests that the human 3D airway models may predict a more realistic, in-
vivo-like response; whereas, 2D cultures might overestimate a potentially toxic effect of nanoparticles.  
 
c. 3D skin models in genotoxicity testing: 
The current status of the validation efforts for the reconstructed skin micronucleus test (RSMN) and RS 
comet assay was presented. Experimental data were shown from an international validation effort that 
started in 2006, with support from Cosmetics Europe (CE) and the German Federal Ministry for 
Education and Research (BMBF). This validation project is part of a strategy of the CE Genotoxicity Task 
Force towards developing an in-vitro-only genotoxicity testing strategy for cosmetic ingredients [10, 11]. 
This project was initiated as a result of the 7th Amendment to the EU Cosmetics Directive, which bans in 
vivo genotoxicity testing for cosmetics, effective since 2009 [12]. Addressing limitations of the skin 
assays discussed at the 5th IWGT in Basel [4], the CE project has added more coded chemicals to the 
validation dataset and also has investigated the metabolic competency of commercially available 3D 
human RS skin models, specifically EpiDermTM [13] and Phenion® FT [14, 15]. It was found that the 
metabolic competency of these RS models is similar to native human skin [13, 14], thereby confirming 
that RS skin models have in-vivo-like metabolic properties, consistent with their use as ‘2nd tier’ assays to 
follow-up on positive results from standard 2D testing battery assays. Advantageously, the use of comet 
and MN RS assays allows the investigation of all key modes of genotoxic activity mandatory for 
regulatory testing (albeit in the form of indicator assays), which should help improve the sensitivity of 





i. The reconstructed skin comet assay (RS comet), validation data and 
examples of regulatory use  
The state of RS comet assay protocol development [16] was discussed by the WG, with presentation of 
data from the first two phases of the validation exercise. In addition, the final protocol used for the 
validation study was presented, including criteria for assay validity and data evaluation. Phenion® Full-
Thickness (FT) skin tissues were used for the validation, although the general suitability of another FT skin 
tissue (EpiDerm FTTM) also has been shown [16]. For FT tissues consisting of keratinocytes and fibroblasts, 
the protocol foresees analyzing both cell types with the alkaline version of the comet assay to identify a 
wide spectrum of DNA damage. In the standard protocol, tissues are treated by repeated dosing at 48, 24 
and 3 h before dissociation of the tissues; in a second experiment, this protocol was amended by the 
addition of the DNA repair inhibitor, aphidicolin, in cases where there were negative or equivocal findings 
in the first RS comet experiment. 
Laboratories from Europe and the USA participated in the testing of 30 blinded chemicals. After decoding, 
independent statistical analysis revealed an overall accuracy (concordance) of 80% (sensitivity 73%, 
specificity 87%) when compared to in vivo animal genotoxicity test outcomes. After the IWGT meeting, 
further blinded chemicals were tested to increase the overlap with chemicals tested in the RSMN assay. 
This resulted in an increase of the RS comet assay’s predictivity, to an overall accuracy of 83% (sensitivity 
77%, specificity 88%)[17]. The positive predictivity increased when the RS comet and RSMN assays are 
combined in a test battery approach [18].  
In addition, the suggested use of the RS comet as a 2nd tier assay, specifically as a follow-up to positive 
findings from the bacterial reverse mutation test (OECD 471 [19]), was discussed during the Tokyo IWGT 
meeting. Cases were reported, in which data on three hair dyes were submitted to the Scientific 
Committee on Consumer Safety (SCCS), an independent expert committee of the EU Commission that 
provides opinions on health and safety risks of non-food consumer products, including cosmetic 
ingredients. Negative data obtained with the RS comet were accepted as part of a weight-of-evidence 
approach, and the hair dyes were considered “safe for use” based on all available data (SCCS/1531/14 
[20], SCCS/1563/15 [21], SCCS/1572/16 [22]). Since 2014, the SCCS has recommended using both the RS 
comet and RSMN assays as a follow-up for suspected misleading positive results from the standard in vitro 
test battery (SCCS/1532/14 [23]). Importantly, the in vivo comet assay efficiently detected in vivo and in 
vitro mutagens [24, 25] and the comet endpoint was therefore considered appropriate for follow-up 





ii. The reconstructed skin micronucleus test (RSMN): validation data 
The multi-year validation efforts for the RSMN using the EpiDermTM skin model have been finalized and 
the chemicals used for validation were decoded shortly before the Tokyo IWGT meeting. Detailed 
experimental data, as well as a preliminary analysis of the validation outcomes, were presented to the 
WG (for details see Pfuhler et al. [18]). Assay development was briefly described [26], transferability and 
protocol optimization efforts [27] were highlighted, and assay validity and data evaluation criteria were 
presented (for details see Pfuhler et al. [18]). The outcome of the blinded testing of over 40 coded 
chemicals was presented, showing an overall assay accuracy of 84%, with a sensitivity of 80% and a 
specificity of 87% when compared to in vivo genotoxicity outcomes. The WG concluded that the RSMN 
assay is an acceptable alternative to the in vivo test and that the high predictivity also demonstrates that 
the test complies with all requirements to be accepted as a 2nd tier test. It should be noted that the final 
validation outcome as per independent analysis of a biostatistician [18] differs slightly from the above 
numbers presented to the WG in Nov 2017. 
The use of the RSMN in the risk assessment process was discussed via a case study on a chemical that 
tested positive in one or both of the standard genotoxicity assays (i.e., mutagenicity and 
clastogenicity/aneugenicity in vitro). Para-phenylene diamine (PPD) tested positive in the Ames test but 
negative in the Hprt mammalian cell mutagenicity assay, and positive for clastogenicity in vitro; PDD, 
however, had a negative in vivo genotoxicity profile (SCCS/1443/11 [28]). Its apparent metabolic 
detoxification in the skin was supported by data indicating that it is N-acetylated when applied to human 
volunteers in a hair dye formulation [29]), and N-acetylated PPD was completely nongenotoxic in vitro, 
including in the Ames test and the in vitro comet assay [30]. Thus, PPD appeared to be a good candidate 
for a case study for follow-up of an in vitro genetox positive test article with skin-based 2nd tier models. 
Subsequent testing in two independent experiments showed negative results for PPD in the RSMN test 
(Figure 4), indicating that the skin-based assay could have been used as an alternative to the animal 
studies to demonstrate this chemical’s lack of genotoxicity via the dermal exposure route.  
 
iii. Establishment of a GLP method and proof of performance 
Following publication of the CE standard method by Dahl et al. in 2011 [27], Covance Laboratories 
performed an in-house validation of the 3D RSMN assay independently of the work described in Section 
2.c.ii above in order to establish a GLP protocol for testing unknown test substances. A summary of the 
results obtained from nine chemicals using the “standard method” 48-h exposure protocol was 
presented to the WG (Table 1). In addition, mixed results exist in the public literature for two 




72-h exposure protocol (as described by Aardema et al. [26]) was also presented. This modified protocol 
incorporates a third addition of the test substance at the 48-h timepoint, followed by harvesting the 
cells at the 72-h timepoint. Replication Index (RI) data for the solvent controls between the 48- and 72-h 
exposure protocols indicated an increase in the number of cells undergoing division during the longer 
(72-h) exposure. In addition, the positive control data (for mitomycin C and vinblastine) also showed 
increases in the percentage of micronucleated binucleate cells (% MNBN) when using the 72-h exposure 
protocol compared to the responses observed using the standard 48-h method. Finally, theoretical and 
experimental data (Tables 2 and 3) were presented on the impact of scoring 1000 binucleate (BN) cells 
from each of two or three treated tissues per test concentration [31]. Both the theoretical and practical 
data showed that scoring 1000 binucleate cells from each of three tissues: 1) reduced the test substance 
concentration where an increase in MNBN cells was statistically significant (compared to the concurrent 
negative control) and 2) reduced the occurrence of scoring zero MNBN per 1000 BN scored. The RI data, 
% MNBN data and results varying by the number of cells scored were discussed, with the detailed 
experimental results and supporting data now published [31]. Documentation of training, management 
approval of SOPs and subsequent implementation, as well as independent Quality Assurance (QA) 
review of the resultant SOPs and protocol are GLP requirements and were satisfied as part of the 
laboratory’s validation process. 
 
iv. Method transfer to China and initial validation data  
The RSMN protocol used for the CE validation also was adapted to the EpiskinTM model with minor 
changes, i.e. milder conditions for cell dissociation and fixation onto the slides, to accommodate 
differences between the different skin models. A description of the protocol and the experiments that 
were performed are available in the paper by Chen et al. [32]. The initiative started at L’Oréal R&I China 
who then transferred the method to two other Chinese laboratories. A validation effort is currently 
ongoing that uses the EpiskinTM model and that is supported scientifically by the CE genotoxicity 
taskforce. All three laboratories have shown proficiency in performing the RSMN assay. At the time of 
the IWGT workshop in Tokyo, results for 5 compounds tested in two of the participating laboratories 
(Guangdong Center for Disease Control and L’Oréal R&I China), and 2 compounds from the third 
laboratory (Zheijiang IFDC) were presented. Based on the 5 compounds, a 100% inter-laboratory 
reproducibility was observed (see Table 4). One compound with mixed results in vivo (cyclohexanone) 
was found to be negative by the two laboratories that tested it. Due to the inconsistency of the in vivo 
results for this compound, it was dropped from the list of compounds for the validation. It also was 




would be advantageous since shipment and export/import of these tissues can be difficult and 
laborious. This would also enable broader access to and acceptance of the RSMN in Asia. 
 
d. Extension of applicability domain – example: nanomaterials  
The liver, airway and skin 3D models described above have all been evaluated for their use in the 
genotoxicity testing of engineered nanomaterials. Iron oxide nanoparticles (both maghemite and 
magnetite) were used to evaluate the performance of the CBMN assay using 3D HepG2 liver spheroids. 
Indeed, the 3D liver spheroids were capable of detecting chromosomal damage induced by the oxidative 
species typically associated with these nanomaterials [33] (Figure 5). A challenge with 3D models is the 
ability to evaluate the penetration of nanoparticles across the biological barrier presented by the 3D 
liver spheroid. This was achieved by the use of x-ray fluorescence mapping, which demonstrated that 
the iron oxide nanoparticles were primarily concentrated within the first few cell layers of the spheroid. 
Some nanoparticles, however, were able to penetrate up to 50 m into the spheroid, although no 
material was evident in the spheroid core. Transmission electron microscopy (TEM) performed on the 
outer cell layers of the spheroid structure demonstrated that the nanoparticles were internalized by 
these cells. 
Standard genotoxicity tests are typically based on a single cell type; however, a key observation in in 
vivo genotoxicity studies conducted with nanomaterials is that the DNA damage induced is often the 
result of secondary genotoxicity associated with inflammation [34, 35]. Lung co-culture models 
comprised of both human lung epithelial cells and differentiated macrophages have therefore been 
established and used for evaluating genotoxicity using the CBMN assay. Dextran-coated ultrafine 
superparamagnetic iron oxide nanoparticles (USPION) were tested in this lung co-culture model, which 
demonstrated that dFe3O4 nanoparticles illicit a genotoxic response in the co-culture, which is absent 
when tested in lung epithelial cells only (i.e. standard 2D CBMN assay; Figure 6) [36]. When cell uptake 
was evaluated in the co-culture model, the nanoparticles were only located in macrophages and were 
not internalized in the lung epithelial cells (where the genotoxicity was detected), thereby indicating a 
secondary genotoxic response was evident in this advanced culture system [36]. This particular model 
utilized a co-culture system, employing a mixture of two cell types, overlaid upon each other. This study 
therefore demonstrates a potential advantage of advanced models comprised of multiple cell types in 
detecting mechanisms in vitro which have not previously been detected in standard genotoxicity testing 
systems. 
The 3D RSMN assay also has been used for the genotoxicity evaluation of silica nanoparticles of two 




damage was compared across both the 3D RSMN and the standard 2D MN assay after standardising the 
test substance concentrations in the 2D and 3D assays by determining the total nanoparticle mass to cell 
number tested. In this study, all exposures ≥100 μg/mL in the 2D CBMN assay resulted in significant 
increases in MN frequency as both test materials were able to readily enter the cells (as determined by 
TEM evaluation). In contrast, 2D-equivalent exposures to the 3D models caused no significant DNA 
damage. Uptake analysis in the 3D skin models using TEM revealed the nanomaterials that had been 
applied topically were not capable of penetrating the 3D microarchitecture of the tissue model; thus, 
there was no direct exposure of the test nanoparticles to the living cells in the model [37]. This study 
demonstrated that, when the RSMN protocol is applied to testing nanomaterials, it is important to 
ensure that the nanomaterials are not used at an excessively high concentration, which would 
compromise the surface of the skin construct and lead to an artifactual result. One such extreme 
concentration of silica nanoparticles was tested by Wills and colleagues, who noted that, although overt 
toxicity was recorded at this concentration, it was likely artifactual. Surface imaging of the 3D RS tissue 
at this toxic concentration revealed excessive particle coverage that likely would have inhibited gas 
exchange at the air interface. Nonetheless, this study demonstrated that the use of RS models for 
nanomaterials offers a more realistic biological barrier that better represents the protective nature of 
the skin’s 3D cellular microarchitecture, thereby improving the physiological relevance of the 
genotoxicity testing results. 
 
3. Discussion 
Why use 3D tissues for genotoxicity testing, and how do they fit into a testing strategy? 
The WG initially discussed the status of development for RS, liver, and airway 3D tissue-based 
genotoxicity assays, as well as their fit within a genotoxicity testing strategy. In concordance with a 
previous expert review [5] and based on the data presented, the IWGT WG agreed that ‘3D tissue 
models offer a more ‘in-vivo-like’ behavior for key parameters like cell viability, proliferation, 
differentiation, morphology, gene and protein expression, and function and therefore provide a valuable 
complement to the classical ‘2D’ cell culture-based assays’. Using more complex, in-vivo-like systems is a 
strong trend in toxicology and in pharmacology that has gained much attention in recent years and, as 
endorsed by this WG for tissue-based genotoxicity assays, is generally seen to provide data that are 
more relevant to evaluating genotoxicity in humans than traditional ‘2D’ assays, [2, 3, 38, 39].  
With regard to their genotoxicity testing strategy fit, the WG initially discussed whether the 3D assays 




currently as a preferred option since it is assumed that regulatory agencies would like to see a 
mutational endpoint, e.g. gene mutations, as part of a submission. It also was pointed out that starting a 
genotoxicity testing program with the 3D assays would be a more time consuming and expensive 
approach compared to using them as follow-up for positive results from the standard 2D test battery. 
With tissue models being more complex, 3D assays are technically more difficult to perform and, 
consequently, their throughput is reduced when compared to 2D assays. One additional argument 
against using 3D assays as 1st tier tests was that the best use of 3D tissues would be to choose the 
respective model according to exposure conditions, e.g., RS tissues for dermal exposures, airway tissues 
for inhalation exposures, and liver tissues for systemic/oral exposures. The WG agreed that such a 
concept ‘allows for exposure-specific investigations’. It should also be noted that most 3D models are 
based on human cells, enhancing the relevance of the results to assessing potential human genotoxicity. 
To summarize the discussion relating to strategic fit, the WG agreed that ‘3D tissue-based genotoxicity 
assays can be used as ‘2nd tier’ assays to follow-up on positive results from standard in vitro assays’ and 
sees the strength of 3D genotoxicity assays as an alternative to animal studies. 
Subsequently, the WG discussed the strategic use of these assays in a ‘test battery’ approach. In this 
context, the expectation was that the assays would be used as follow-up of positive results from the 1st 
tier in vitro testing battery (e.g., Ames and in vitro MN test). The WG agreed that the use of an assay 
(consisting of a specific tissue model and a genotoxicity read-out) for regulatory purposes will depend 
on its validation status. In order to be considered useful as ‘2nd tier’ assays ‘it is important that, for each 
tissue model, the full range of genotoxic damage (leading to mutagenicity, clastogenicity, aneugenicity) 
can be detected’. Therefore, while it would be ideal that each 3D tissue type would be validated for all 
genotoxicity endpoints at the same time, this may not always be the case. It was therefore emphasized 
that ‘these assays can be used in combination or alone depending on the scenario since these 3D models 
are suitable for “endpoint-specific” follow-up of positives from standard in vitro testing battery’. With 
respect to the positioning of 3D assays, the following three scenarios were discussed and agreed:  
(1) in vitro clastogenicity/aneugenicity positives lead to 3D MN testing,  
(2) in vitro mutagenicity positives lead to 3D comet 
(3) in vitro mutagenicity & clastogenicity/aneugenicity positives lead to both 3D comet and 3D MN.   
In this context, it was emphasized that the more frequent scenario likely will address a single positive 
from the standard battery. It is recognized by all WG members that there are other assays/readout 
methods available that could potentially be used in 3D organoid models (e.g., a gene mutation readout 




The focus on the comet and MN assays was triggered by the existing experimental datasets for the 3D 
skin, airway and liver tissues, which was limited to these endpoints.  
How can advantages of in-vivo-like ‘3D’ models be leveraged further? 
Most of the experimental data presented at the meeting were generated with chemicals; however, the 
WG acknowledged that the specific advantages of 3D models in terms of more in-vivo-like ADME 
properties, in particular penetration/absorption, make them an interesting model for studying potential 
genotoxic effects of nanomaterials. Examples presented included the determination of the genotoxic 
potential of silica nanomaterials after dermal exposure. While giving a positive response in standard 2D 
cell culture systems, RS models offer a more realistic biological barrier for testing effects via the dermal 
exposure route and the lack of a genotoxic response in the RS models likely reflect the in vivo situation 
since silica nanomaterials do not penetrate the dermis in vivo [37]. Conversely, in a co-culture model 
with macrophage and lung epithelial cells, it was shown that dFe3O4 nanoparticles were taken up only by 
macrophage cells and not by the lung epithelial cells. Genotoxic effects, likely secondary in nature, were 
detected in lung epithelial cells in the 3D co-culture system but not when exposed in 2D lung cell 
cultures where no macrophages were present [36]. These examples demonstrate advantages of such 
complex in vitro models, leading the WG to conclude that ‘3D tissue-based assays provide a more 
realistic test system to study particulate materials (e.g. nanomaterials), compared to 2D test systems’. It 
was also emphasised that it is critical to have a clear understanding of the fate of the nanomaterials 
used under the respective assay conditions [41] and also to include measurements of cellular uptake 
(e.g. electron microscope analysis of penetration / uptake) to help understand the outcome of the assay. 
In situ characterization and uptake measurements have been recommended by several expert 
committees and are already included in a genotoxicity testing guidance for nanomaterials [41]. The WG 
also recommends that any future guideline for ‘3D’ model-based genotoxicity assays consider these 
factors when testing nanomaterials. 
Discussion of the validation status of 3D liver, airway and skin-based genotoxicity assays 
The three different tissue models are at various stages of development and validation, with the RS 
model being the only one that has undergone formal validation. For assays based on airway tissue and 
liver organoids, existing data is sparser [8, 42-44]. While consensus statements specific to each tissue 
model are captured further below, for both the liver and airway  the WG encourages ‘development of a 
robust protocol and testing of an initial set of chemicals representing expected positives and negatives 
covering different chemical classes before following up with other validation steps, like transferability, 




supports the goal of having validated methods that enable exposure-specific assessments. The 
respective models have the capacity to represent dermal, oral and inhalation exposure routes in safety 
assessment and there was agreement supporting efforts directed at the continued development and 
validation of these models.   
Next, the organ-specific status was discussed in more detail and the WG agreed that for 3D liver 
spheroids ‘Initial data show that the MN assay can be applied to 3D liver spheroids and the WG 
encourages further development of this assay’. During the discussion of the protocol, it was 
recommended that for further protocol development, exposure time and the concentration of 
cytochalasin B could be further optimized, and the determination of cell cycle time might be useful in 
this context. Experience with endpoints other than MN, however, is much more limited and it was 
concluded that ‘the lack of 3D liver assays that can detect substances that induce gene mutation is 
considered a gap and the development of such an assay is strongly encouraged. Some preliminary data 
indicate that the comet assay can be useful in this respect [48]. It was also mentioned that HepaRG cell-
derived 3D liver spheroids are being investigated in detail within the framework of the EU HORIZON 
2020 project PATROLS (www.patrols-h2020.eu), including characterization of their metabolic 
competence. 
For 3D airway model-based assays, the WG concluded, based on the data presented, that ‘Initial data 
show that the comet assay can be applied to the 3D airway models and the WG encourages further 
development of this assay’. It was emphasized that ‘the lack of 3D airway assays that can detect 
aneugenicity is considered a gap and the development of such an assay is strongly encouraged.’ In this 
context, several WG members pointed out that the limited proliferation rate of the cells in the 3D airway 
model currently makes the MN assay problematic. More effort is needed to resolve this problem. User 
experience was shared, and it was pointed out that proliferation rates will depend on the cell type and 
source used for the model. It was also suggested that, instead of MN, testing of ɣH2AXmay be helpful, 
since cells do not need to divide for this readout system. However, this is an indicator test that does not 
detect aneugens, and further research in this area is therefore highly encouraged. 
It also was pointed out that only limited information on the metabolic competence of the 3D lung 
models was available at the time of the WG meeting [49] and that a better understanding in this regard 
would be important. It is encouraging that, subsequent to the IWGT WG meeting, data on the metabolic 
competence of the human ALI airway model has begun to appear [8]. 
In contrast to liver and airway 3D models, development of 3D skin model-based genotoxicity assays 




exposures. This work is in accordance with the recommendation of Maurici and colleagues that was 
developed at an expert meeting charged with the question of what in-vitro-only approaches would be 
most appropriate for genotoxicity hazard identification [50]. This question originated in the context of 
the EU Directive for cosmetic ingredients which prohibits animal testing for genotoxicity [12] and the 
first experimental data were published shortly after by Curren et al. [51]. Based on the data presented at 
the Tokyo IWGT meeting, which reflect the outcome of a multi-year international validation exercise 
[17, 18], the WG concluded that ‘following extensive validation and practice (in use for over 10 years) we 
are now in the position to define standard protocols for the 3D skin comet and RSMN assays’. 
Furthermore, it was concluded that ‘transferability of the assays to a large number of laboratories across 
3 continents has been demonstrated’, and it was emphasized that ‘the assays are now available at 
several CROs and are performed under GLP (Good Laboratory Practice)’. 
There was considerable discussion specific to the RSMN protocol, since initial work for this assay used a 
48 h treatment protocol (two exposures with a 24 h interval), whereas there is growing evidence from 
the validation dataset [18] as well as CRO experience [31] that a 72 h protocol with three exposures is 
superior since it increased the sensitivity of the assay. The WG concluded that ‘validation data and CRO 
experience show that the 72 h protocol for the RSMN has higher sensitivity than the 48 h protocol and 
we therefore agree that the assay can be routinely performed using the 72 h protocol’. Importantly, with 
this move to a 72 h protocol, the specificity of the assay decreased only marginally. It is expected that 
these findings will influence protocol modifications such that the initial testing of an unknown substance 
will start with a 72 h and 3-exposure protocol rather than with the original 48 h protocol.  
The key elements of validation that help assess the maturity of an assay were then discussed, i.e. 
reproducibility, sensitivity, specificity and predictive capacity. It was concluded from the data presented 
that ‘international validation studies with coded chemicals have demonstrated good intra- and inter-
laboratory reproducibility of the methods’, and that ‘through the testing of 56 coded chemicals across 
assays (3D skin comet and RSMN), the combination of the methods has been shown to be highly 
predictive of the expected genotoxicity in vivo’. The WG members agreed that the RS comet and RSMN 
assays have reached an advanced stage of maturity and concluded ‘that the 3D skin comet and 
micronucleus assays are now sufficiently validated to move towards the development of individual OECD 
Test Guidelines’. Although the WG considered the assays to have undergone sufficient validation, it is 
envisaged that an independent peer review of the validation study will need to be carried out, as 
recommended in OECD Guidance Document 34 [45], before developing an OECD TG. This can be 




independent review of validation data, such as, for example, the EURL ECVAM Scientific Advisory 
Committee (ESAC). 
4. Conclusions 
The workshop demonstrated that extensive progress has been made in the last few years on the 
development of 3D genotoxicity models. Different 3D culture models are now available that represent 
the major routes of exposure: dermal, systemic (liver spheroids, organ on a chip), and inhalation. The 
IWGT WG believes that the 3D skin comet and MN assays are now sufficiently validated to begin the 
development of individual OECD Test Guidelines. Although the WG considered the assays to have 
undergone sufficient validation, an independent peer review of the validation study will need to be 
carried out as recommended by OECD Guidance Document 34.  
Genotoxicity assays using the two other 3D models are at an early stage of development and still do not 
sufficiently cover the three key endpoints of genotoxicity. For the 3D airway model, clastogenicity and 
gene mutation can be measured, at least indirectly, by the comet assay, but the development of a 3D 
airway MN model for detection of aneuploidy is desirable. Likewise, for the 3D liver model, where MN 
can be detected, a test that can evaluate gene mutations is essential. In addition, for airway 3D models, 
‘more information on the metabolic competence of the cells is considered important.’  Finally, for both 
the liver and airway models the considerable hurdle of assay validation remains: thus, we ‘recommend 
developing a robust protocol and testing of an initial set of chemicals representing expected positives 
and negatives covering different chemical classes before following up with other validation steps, being 
transferability, intra- and inter-laboratory reproducibility, applicability domain and predictive capacity’ 
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 Figure 3: LDH (A) and IL-8 (B) response of MucilAir, BEAS-2B, and A549 to air exposure (without any 
CeO2). The biological LDH (A) and IL-8 (B) response (y axis) of the cells tested is expressed as %LDH and 
%IL-8 of air-exposed samples (n = 3) divided by the average expression of incubator control samples (n = 
2). Indicated are the average and standard deviation of the resulting three ratios multiplied by 100 to 


























Figure 4 a, b: RSMN assay with p-phenylene diamine – two independent experiments 
 














































































Figure 5: Micronucleus frequency induced by dextran coated iron oxide nanoparticles in HepG2 cells 
cultured in standard 2D monolayer format and in 3D spheroid format. BaP at 8 µM was included as a 









Figure 6a, b: Quantification of chromosomal damage and cell viability of 16HBE14o- cells following 
dSPION exposure. (A) Mono-cultured 16HBE14o- cells treated with Fe3O4; (B) lung co-culture model 
consisting of 16HBE14o- lung epithelial cells and differentiated THP-1 macrophages, treated with Fe3O4 
dSPION. *p < 0.05 when compared to negative control (0 µg/ml).  MMC (0.1 µg/ml) was used as positive 
control (micronuclei frequency 4.01%).  
Figures 5 and 6 were reproduced with permission from Evans et al, 2019 (34); this open access article is 













Table 1: Summary of the testing (using EpiDerm™) for the standard 48-hour method as performed at 




Table 2: Statistical Power calculations - 1000 cells scored for 2 replicates per group. From Kidd [31] 
 
Control  
Incidence (Mean MNBN 
cell frequency (%)) 
Test Group(1)  
(Mean MNBN cell 
frequency (%)) 
Difference (Test – 
Control) (Mean MNBN 
cell frequency (%)) 
Fold difference (Test / 
Control) 
0/2000 (0.000) 5/2000 (0.250) 0.250 N/A 
1/2000 (0.050) 7/2000 (0.350) 0.300 7.00 
2/2000 (0.100) 9/2000 (0.450) 0.350 4.50 
3/2000 (0.150) 10/2000 (0.500) 0.350 3.33 
4/2000 (0.200) 12/2000 (0.600) 0.400 3.00 
5/2000 (0.250) 13/2000 (0.650) 0.400 2.60 
6/2000 (0.300) 15/2000 (0.700) 0.450 2.50 
 (1) Response in Test group that could be detected as statistically significant 
Assuming a control incidence of 0.100%, 1000 cells scored for 2 replicates would allow a difference of approximately 0.350% 
(4.50 fold increase) between groups to be detected as statistically significant at the 5% level using a one-sided Chi-squared test. 
 
Table 3: Statistical Power calculations - 1000 cells scored for 3 replicates per group. From Kidd [31] 
Control  
Incidence (Mean MNBN 
cell frequency (%)) 
Test Group(1)  
(Mean MNBN cell 
frequency (%)) 
Difference (Test – 
Control) (Mean MNBN 
cell frequency (%)) 
Fold difference (Test / 
Control) 
0/3000 (0.000) 5/3000 (0.167) 0.167 N/A 
1/3000 (0.033) 7/3000 (0.233) 0.200 7.00 
2/3000 (0.067) 9/3000 (0.300) 0.233 4.50 
3/3000 (0.100) 10/3000 (0.333) 0.233 3.33 
4/3000 (0.133) 12/3000 (0.400) 0.267 3.00 
Covance Published Literature
Genotoxicity Compound 48-hour 48-hour
Mitomycin C Positive Positive
Methyl methansulphonate Positive Positive
n-Ethylnitrosourea Positive Positive
Aneugens Vinblastine Positive Positive
Cyclophosphamide Negative Mixed results












5/3000 (0.167) 13/3000 (0.433) 0.267 2.60 
6/3000 (0.200) 15/3000 (0.500) 0.300 2.50 
 (1) Response in Test group that could be detected as statistically significant 
Assuming a control incidence of 0.100%, 1000 cells scored for 3 replicates would allow a difference of approximately 0.233% 
(3.33 fold increase) between groups to be detected as statistically significant at the 5% level using a one-sided Chi-squared test. 
 















L’Oréal GDCDC ZIFDC 
      48h 48h 48h 
Mytomycin C 50-07-7 Positive Positive Positive Positive 
Vinblastine 143-67-9 Positive Positive Positive Positive 
5-Fluorouracil 120-83-2 Positive Positive Positive Not tested 
2,4-Dichlorophenol 108-94-1  Negative Negative  Negative  Not tested 
Cyclohexanone  108-94-1  Negative/Positive Negative  Negative  Not tested 
 
 
